Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health (NASDAQ:COSM) has signed an exclusive distribution agreement with Innova Healthcare, one of Saudi Arabia’s largest retail pharmacy networks, for its Sky Premium Life food supplements across the Kingdom of Saudi Arabia. The deal includes an initial purchase order of 126,000 units.
Innova is appointed sole distributor for registration, distribution, promotion, marketing, logistics and sales across pharmacies, retail shops and online platforms, for an initial five-year term with an option to renew for another five years. Innova also receives a first right of refusal on new Cosmos Health products during the term. Cosmos Health expects to receive orders of more than 5 million units over the initial five-year period, based on current assumptions. The agreement provides access to Innova’s network of 250+ pharmacies in 12 Saudi cities and villages and entry into a Saudi nutraceuticals market estimated at $3.26 billion in 2024 and forecast to reach $5.96 billion by 2033.
Cosmos Health (NASDAQ:COSM) reported record Q2 2026 revenue of $18.99 million, up 28.8% year over year, and first‑half revenue of $36.91 million, up 29.7%. Adjusted revenue reached $19.32 million in Q2 and $37.72 million in H1. Adjusted gross profit rose 58.4% to $1.84 million in Q2, with adjusted gross margin expanding 165 bps to 9.54%, while operating expenses increased 16.5%, below the revenue growth rate.
Net loss widened to $6.09 million in Q2 and $8.89 million in H1, largely due to $2.65 million of non‑cash fair‑value charges. Adjusted EBITDA improved slightly to a loss of $1.13 million in Q2. Total liabilities fell 13.3% to $40.79 million, stockholders' equity increased 12.2% to $20.67 million, and liquid assets stood at $4.15 million. Under a $5.0 million share repurchase program running through December 31, 2026, Cosmos has bought back about 5.1 million shares for $1.11 million to date.
Cosmos Health (NASDAQ:COSM) announced the active development of a flexible, technology-driven digital subscription platform to unify its proprietary consumer health products across both B2C and B2B channels. Customers will be able to start via a free nutritionist consultation, an AI-powered assistant, or by building their own package.
The platform is being designed to support consumer subscriptions at chosen frequencies, corporate subscriptions for employee wellness and gifting with multi-recipient tools, tiered pricing, centralized billing, and one-time or gift purchases. According to Cosmos Health, the initiative builds on its U.S. NOOR Collagen subscription model, which has achieved an early repeat purchase rate above 60%, and is intended to scale into international markets and support a recurring-revenue business model.
Cosmos Health (NASDAQ:COSM) reported that it has repurchased an additional 274,000 shares of its common stock in the open market at an average price of approximately $0.2554 per share. In total, the company has repurchased about 5,112,000 shares for approximately $1.11 million under its previously announced share repurchase program of up to $5 million.
Cosmos Health stated it intends to continue open market repurchases, subject to market conditions, under the program, which runs through December 31, 2026 and may be renewed at the company’s discretion. Management said the buybacks reflect its view that the shares remain undervalued.
Cosmos Health (NASDAQ:COSM) reported that it has repurchased an additional 250,000 shares of common stock in the open market at an average price of about $0.2782 per share. This brings total buybacks under its existing repurchase program to 4,838,000 shares for approximately $1.04 million.
The authorized program allows for share repurchases of up to $5 million and is set to run through December 31, 2026, with the option for renewal at the company’s discretion. Cosmos Health plans to continue open market repurchases, subject to market conditions, in accordance with SEC Rules 10b5-1 and 10b-18.
Cosmos Health (NASDAQ:COSM) announced it has repurchased an additional 100,000 shares of common stock in the open market at an average price of about $0.2928 per share. This brings total repurchases under its previously announced up to $5 million share buyback program to 4,588,000 shares for approximately $970,000.
According to Cosmos Health, shares may be repurchased in the open market, through privately negotiated transactions, or other permitted means, in line with SEC Rules 10b5-1 and 10b-18. The program runs through December 31, 2026, may be renewed at the company’s discretion, and the company intends to continue open market repurchases subject to market conditions.
Cosmos Health (NASDAQ:COSM) reported that it has repurchased an additional 133,000 common shares in the open market at an average price of about $0.298 per share. This brings total repurchases under its existing share buyback program to approximately 4,488,000 shares, for about $941,000 in aggregate consideration.
According to Cosmos Health, the authorized repurchase program allows for up to $5 million in buybacks and runs through December 31, 2026. The company may repurchase shares in the open market, via privately negotiated transactions, or other permitted methods, and intends to continue open market repurchases subject to market conditions.
Cosmos Health (NASDAQ:COSM) announced that it has repurchased an additional 215,000 common shares in the open market at an average price of approximately $0.325 per share. This brings total repurchases under its share buyback program to 4,355,000 shares for approximately $901,000.
The previously announced program authorizes repurchases of up to $5 million and runs through December 31, 2026. According to Cosmos Health, repurchases may occur in the open market, via privately negotiated transactions, or other permitted methods, in line with SEC Rules 10b5-1 and 10b-18. The company intends to continue open market repurchases, subject to market conditions, and the program may be renewed at its sole discretion.
Cosmos Health (NASDAQ:COSM) announced a five-year commercialization agreement with Libytec Pharmaceutical for its type‑2 diabetes medicine DIABIT-IS X (sitagliptin phosphate) in Greece. Through subsidiary Cana Laboratories, Cosmos will supply DIABIT-IS X, while Libytec will manage distribution, medical information, and promotion to physicians, pharmacies, and hospitals nationwide.
DIABIT-IS X, available as 50 mg and 100 mg film‑coated tablets, is a generic alternative to Merck’s Januvia, which together with Janumet generated about $4.5 billion in global sales in 2022. As a prescription drug in a publicly reimbursed class, it is expected to be accessible via Greece’s national health insurance (EOPYY), potentially broadening its reach. According to Cosmos Health, the partnership is expected to contribute meaningfully to revenue and cash flow and supports its strategy to expand in the European sitagliptin market and other regional markets over time.
Cosmos Health (NASDAQ:COSM) has launched a subscription-based purchasing model for its proprietary consumer health brands, starting with NOOR Collagen in the United States. Early data for this product show a repeat purchase rate above 60% and margins in excess of 50%.
The company plans to roll out the subscription model across additional brands and global markets. According to Cosmos Health, the approach is intended to generate recurring revenue, enhance cash-flow visibility, enable product bundling, offer access to nutrition and wellness guidance, and deepen customer loyalty and lifetime value.